WinstonWınston
Back
Stock

Newron Pharmaceuticals S.p.A.

NP5.DE
14
Biotechnology · Healthcare
Also trades as: 0QOI.L GBP 0.08 (+5.43%)
Price
€8.44
+1.04 (+14.05%)
Market Cap
€175.6M
Exchange
Frankfurt Stock Exchange
Winston Score
14
Winston is worried
Weak fundamentals across most pillars.
Data as of Oct 10, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Weak
1/30
Growth
Weak
2/20
Cash Flow
Weak
0/10
Stability
Weak
0/10
Valuation
Data not available
0/10
Ownership
Good
10/15
Dividends
Not counted
n/a

13 of 95 counted points = Winston Score 14. Pillars marked n/a do not apply to this company and are left out of the total.

Track this stock — start free trial

Share count rising — dilution

+11.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 17.8M (2021) → 20.0M (2025)

§Winston Score History

The full picture

Newron Pharmaceuticals is a small Italian biotech company that discovers and develops drugs for diseases of the nervous system. Its main product is Xadago (safinamide), a treatment for Parkinson's disease that is sold in Europe and the United States. The company focuses on conditions like Parkinson's and rare neurological disorders, selling primarily to patients through partnerships with larger pharmaceutical companies.

Newron makes money mainly through licensing deals and royalties, meaning it earns fees when partner companies sell its drugs rather than selling directly to patients itself. That explains the very high gross margin despite the company losing money overall. It is headquartered in Milan, Italy, and operates at a small scale with a market value of around $300 million. Because Newron depends heavily on a limited number of drugs and partnership agreements, its biggest risk is that any setback in its pipeline — a failed clinical trial or a lost licensing deal — could significantly hurt its revenue and cash position.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-73.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

€15M/ year

↑ Rising (+10% vs prior year)

79.2% of revenue

4.4x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

13.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~9 months

€33M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Newron Pharmaceuticals S.p.A. is putting 79% of revenue into R&D and that number is rising. That's 4.4x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
0.0%
Thin — 0.0% gross margin
Profit after running costs
Operating Margin
-520.5%
Losing money on operations — -520.5%
Return on the money invested
ROCE
-60.4%
Weak — -60.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-82.7%
Shrinking sales (-82.7% YoY)
Profit growth
EPS YoY
-213.6%
Earnings shrinking (-213.6% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-115.9%
Burning cash (-115.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
33.23
Heavy debt load (33.23)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial